Clinical trial · Observational
Serum Betatrophin Levels in Normal-Weight and Overweight Adolescents With PCOS
Evaluation of Serum Betatrophin Levels in Normal-Weight and Overweight Adolescents With Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in adolescents and women of reproductive age and is frequently associated with insulin resistance and an increased risk of metabolic complications. The mechanisms underlying these metabolic abnormalities are not fully understood. Betatrophin (angiopoietin-like protein 8, ANGPTL8) is a liver- and adipose tissue-derived protein involved in lipid and glucose metabolism and has been suggested to be associated with insulin resistance and metabolic stress. This study aims to evaluate serum betatrophin levels in adolescents with PCOS compared with age-matched healthy controls. Adolescents with PCOS will also be categorized according to body mass index (BMI) as normal-weight or overweight to investigate the potential influence of body weight. Additionally, the relationships between betatrophin levels and anthropometric parameters, hormonal profiles, and markers of insulin resistance will be examined.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Betatrophin | — | UNRESOLVED | — |
| Body Mass Index (BMI) | — | UNRESOLVED | — |
| Insulin Resistance | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome (PCOS) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Serum betatrophin levels | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Overweight PCOS (Group I)
- description
- Adolescent females diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria, with a body mass index (BMI) ≥25 kg/m². Participants have not received prior medical or surgical treatment for PCOS and do not have chronic diseases such as diabetes, cardiovascular, thyroid, or rheumatologic disorders.
- interventionNames
- Other: Serum betatrophin levels
- label
- Normal-weight PCOS (Group II)
- description
- Adolescent females diagnosed with PCOS according to the Rotterdam criteria, with a BMI \<25 kg/m². Participants have not received prior medical or surgical treatment for PCOS and do not have chronic diseases including diabetes, cardiovascular, thyroid, or rheumatologic disorders.
- interventionNames
- Other: Serum betatrophin levels
- label
- Healthy Controls (Group III)
- description
- Age-matched adolescent females without PCOS or any chronic endocrine, metabolic, or systemic diseases. Participants have not received prior medical or surgical treatment affecting metabolic or hormonal status.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 16 Years
- Maximum age
- 23 Years
Show eligibility criteria text
Inclusion Criteria: * Adolescent females aged 16-23 years * Post-menarche status * Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria (for Groups I and II) * Age-matched healthy females without PCOS for control group (Group III). * Ability and willingness to provide informed consent/assent * Willingness to comply with study procedures and blood sample collection Exclusion Criteria: * Cardiovascular diseases including hypertension * Type 1 or type 2 diabetes mellitus * Morbid obesity * Primary adrenal insufficiency * Uterine fibroids * Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease * Hepatic dysfunctions * Renal insufficiency * Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9 * Neurologic diseases * Psychiatric disorders * Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever * History of any malignancy * History of exposure to chemotherapeutic agents or radiotherapy
References
Publications (4)
- BACKGROUNDWang H, Lai Y, Han C, Liu A, Fan C, Wang H, Zhang H, Ding S, Teng W, Shan Z. The Effects of Serum ANGPTL8/betatrophin on the Risk of Developing the Metabolic Syndrome - A Prospective Study. Sci Rep. 2016 Jun 27;6:28431. doi: 10.1038/srep28431. PMID 27345212
- BACKGROUNDVarikasuvu SR, Panga JR, Satyanarayana MV. Circulating Angiopoietin-like 8 protein (ANGPTL8/Betatrophin) in patients with polycystic ovary syndrome: a systematic review and multi effect size meta-analysis. Gynecol Endocrinol. 2019 Mar;35(3):190-197. doi: 10.1080/09513590.2018.1536736. Epub 2019 Jan 7. PMID 30614305
- BACKGROUNDHe Y, Hu W, Yang G, Guo H, Liu H, Li L. Adipose Insulin Resistance and Circulating Betatrophin Levels in Women with PCOS. Biomed Res Int. 2020 Jan 21;2020:1253164. doi: 10.1155/2020/1253164. eCollection 2020. PMID 32076603
- BACKGROUNDDubey P, Reddy S, Sharma K, Johnson S, Hardy G, Dwivedi AK. Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease. Curr Cardiol Rep. 2024 Jun;26(6):483-495. doi: 10.1007/s11886-024-02050-5. Epub 2024 Apr 3. PMID 38568339